OM Pharma Overview
- Year Founded
-
1937
- Status
-
Acquired/Merged
- Employees
-
500
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
OM Pharma General Information
Description
Developer and manufacturer of pharmaceuticals intended for recurrent respiratory and urinary tract infections and treatment of vascular diseases. The company offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products, research, manufacturing and sale of biotechnological and synthetic drugs, thereby helping patients to have treatments of acute and chronic immunological disorders resulting from inflammation and infections.
Contact Information
Website
www.ompharma.com(Operating Subsidiary)
Corporate Office
- Rue du Bois-du-Lan 22
- Meyrin 2
- 1217 Geneva
- Switzerland
Corporate Office
- Rue du Bois-du-Lan 22
- Meyrin 2
- 1217 Geneva
- Switzerland
OM Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OM Pharma Comparisons
Industry
Financing
Details
000000
000000
OM Pharma Competitors (3)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Santhera Pharmaceuticals | Formerly VC-backed | Pratteln, Switzerland | 00 | 00000 | 000000000 | 00000 |
| Endogena Therapeutics | Venture Capital-Backed | Zurich, Switzerland | 00 | 000.00 | 00000000000 | 000.00 |
| Airway Therapeutics | Venture Capital-Backed | Marietta, GA | 00 | 0000 | 00000000000 | 0000 |
OM Pharma Patents
OM Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3165209-A1 | 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments | Pending | 11-Mar-2020 | 0000000000 | |
| AU-2021236256-A1 | Novel hydroquinone derivaties | Pending | 11-Mar-2020 | 0000000000 | |
| EP-4118069-A1 | 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments | Pending | 11-Mar-2020 | 0000000000 | |
| EP-3878837-A1 | 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments | Inactive | 11-Mar-2020 | 0000000000 | 0 |
| JP-2023517693-A | New hydroquinone derivative | Pending | 11-Mar-2020 | C07D251/20 |
OM Pharma Executive Team (9)
| Name | Title | Board Seat |
|---|---|---|
| Laurent Perritaz | Chief Financial Officer | |
| Patricia Moles-Licata | Chief Human Resources and Communication Officer | |
| Elodie Convercey | Chief Marketing Officer | |
| Anna Thomas | Chief Scientific Officer | |
| Pascal Schumacher | Chief Commercial Officer |
OM Pharma Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 0000000 00.0 | OM Pharma | Chairman & Senior Advisor | 000 0000 |
OM Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
OM Pharma Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
OM Pharma FAQs
-
When was OM Pharma founded?
OM Pharma was founded in 1937.
-
Who is the CEO of OM Pharma?
Roch Ogier Ph.D is the CEO of OM Pharma.
-
Where is OM Pharma headquartered?
OM Pharma is headquartered in Geneva, Switzerland.
-
What is the size of OM Pharma?
OM Pharma has 500 total employees.
-
What industry is OM Pharma in?
OM Pharma’s primary industry is Drug Discovery.
-
Is OM Pharma a private or public company?
OM Pharma is a Private company.
-
What is the current valuation of OM Pharma?
The current valuation of OM Pharma is 00000.
-
What is OM Pharma’s current revenue?
The current revenue for OM Pharma is 00000.
-
Who are OM Pharma’s investors?
CSL Vifor has invested in OM Pharma.
-
Who are OM Pharma’s competitors?
Santhera Pharmaceuticals, Endogena Therapeutics, and Airway Therapeutics are competitors of OM Pharma.
-
When was OM Pharma acquired?
OM Pharma was acquired on 18-Sep-2020.
-
Who acquired OM Pharma?
OM Pharma was acquired by Optimus Holding.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
